Investors & Media

Sandoz spin-off

Novartis has announced an intention to separate the Sandoz business to create a standalone company by way of a 100% spin-off.

Latest News

Sep 26, 2023

Sandoz receives European Commission approval for Tyruko® (natalizumab), first and only biosimilar for multiple sclerosis in Europe

Sep 25, 2023

Novartis confirms Sandoz Spin-off for October 4, 2023

Sep 18, 2023

Sandoz receives positive CHMP opinion for breast and gastric cancer biosimilar trastuzumab

Media Releases

Find announcements about Sandoz products, programs and company updates.

Media Library

Visit the Sandoz media resource center to view and download media resources including documents, images and videos.

Media Contacts

Find contacts at Sandoz for media and journalist inquiries.

Novartis Annual Reporting Suite

Access and download our integrated report, annual regulatory filings, and other disclosures.

Novartis Financial Data

Novartis provides the following information on the Group's strong financial performance since its creation in 1996.

Sandoz Capital Markets Day

June 2023

Sandoz hosted two Capital Markets Days (CMDs), on June 8 and June 12, at the New York stock exchange and the London stock exchange. The goal of both events was to outline its strong heritage, reshaped growth strategy and plans for sustainable market leadership, following the proposed 100% spin-off from Novartis in the second half of this year.

Click here to view key materials including the press release and CMD deck, as well as to listen to the recordings.

Learn more

Sandoz Leadership